Soriano V, Gutiérrez M, Vallejo A, Aguilera A, Calderón E, Franco E
Instituto de Salud Carlos III, Madrid.
Med Clin (Barc). 1995 Sep 9;105(7):246-50.
HTLV-I is a human retrovirus which has been implicated in the genesis of tropical spastic paraparesia (TSP), adult T-cell leukemia (ATL) and some patients with uveitis, subacute arthropathies and lymphocytary alveolitis. The virus is endemic in some zones of the Caribbean countries, Japan, subsaharian Africa, Middle East and Melanesia. Given that HTLV-I is transmitted by similar routes as HIV, anti-HTLV-I antibody screening is carried out in blood donors in some countries.
The clinical, epidemiologic and virologic characteristics of the patients with HTLV-I infection identified in Spain up to November 1994 are described.
Twenty-four Spanish residents have been identified with HTLV-I infection including 16 Spaniards and 8 immigrants from endemic areas. Thirteen (53%) are males and 11 (47%) females. Most of the persons born in Spain (12/16; 75%) have lived in endemic areas or have maintained sexual relations with natives of them. Four patients were diagnosed with TSP, three with ATL and another with lymphomatoid granulomatosis and angiocentric T-cell lymphoma. The remaining patients were asymptomatic at the time of diagnosis. Two HTLV-I carriers were identified on blood donation.
HTLV-I infection is present in Spain being found in Spanish natives and, to a lesser degree, in immigrants from endemic areas. It is therefore recommendable to analyze the cost-benefit of anti-HTLV-I screening in blood donors.
人类嗜T淋巴细胞病毒I型(HTLV-I)是一种人类逆转录病毒,与热带痉挛性截瘫(TSP)、成人T细胞白血病(ATL)以及一些葡萄膜炎、亚急性关节病和淋巴细胞性肺泡炎患者的发病有关。该病毒在加勒比国家、日本、撒哈拉以南非洲、中东和美拉尼西亚的一些地区呈地方性流行。鉴于HTLV-I与HIV的传播途径相似,一些国家对献血者进行抗HTLV-I抗体筛查。
描述了截至1994年11月在西班牙确诊的HTLV-I感染患者的临床、流行病学和病毒学特征。
已确认24名西班牙居民感染了HTLV-I,其中包括16名西班牙人和8名来自流行地区的移民。13名(53%)为男性,11名(47%)为女性。大多数在西班牙出生的人(12/16;75%)曾生活在流行地区或与当地居民有过性关系。4名患者被诊断为TSP,3名患者被诊断为ATL,另一名患者被诊断为淋巴瘤样肉芽肿和血管中心性T细胞淋巴瘤。其余患者在诊断时无症状。在献血时发现了2名HTLV-I携带者。
西班牙存在HTLV-I感染,在西班牙本地人中发现,在较小程度上也在来自流行地区的移民中发现。因此,建议分析对献血者进行抗HTLV-I筛查的成本效益。